Targeting Phospholipid Metabolism in Cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
All cancers tested so far display abnormal choline and ethanolamine phospholipid metabolism, which has been detected with numerous magnetic resonance spectroscopy (MRS) approaches in cells, animal models of cancer, as well as the tumors of cancer patients. Since the discovery of this metabolic hallmark of cancer, many studies have been performed to elucidate the molecular origins of deregulated choline metabolism, to identify targets for cancer treatment, and to develop MRS approaches that detect choline and ethanolamine compounds for clinical use in diagnosis and treatment monitoring. Several enzymes in choline, and recently also ethanolamine, phospholipid metabolism have been identified, and their evaluation has shown that they are involved in carcinogenesis and tumor progression. Several already established enzymes as well as a number of emerging enzymes in phospholipid metabolism can be used as treatment targets for anticancer therapy, either alone or in combination with other chemotherapeutic approaches. This review summarizes the current knowledge of established and relatively novel targets in phospholipid metabolism of cancer, covering choline kinase α, phosphatidylcholine-specific phospholipase D1, phosphatidylcholine-specific phospholipase C, sphingomyelinases, choline transporters, glycerophosphodiesterases, phosphatidylethanolamine N-methyltransferase, and ethanolamine kinase. These enzymes are discussed in terms of their roles in oncogenic transformation, tumor progression, and crucial cancer cell properties such as fast proliferation, migration, and invasion. Their potential as treatment targets are evaluated based on the current literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling
Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., & Chen, J. (2001) · Science · doi:10.1126/science.1066015 · Cited by 1,055
Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology
Kirkegaard, T., Roth, A. G., Petersen, N. H. T., Mahalka, A. K., Olsen, O. D., Moilanen, I., Zylicz, A., Knudsen, J., Sandhoff, K., Arenz, C., et al. (2010) · Nature · doi:10.1038/nature08710 · Cited by 519 · cited 1×
“However, on the other hand, ASM-deficient human patients suffering from Niemann–Pick disease have cells with lysosomal storage disorders and significantly decreased lysosomal stability (119), suggesting that ASM is essential for maintaining normal lysosomal integrity.”
BackgroundGDE2 Promotes Neurogenesis by Glycosylphosphatidylinositol-Anchor Cleavage of RECK
Park, S., Lee, C., Sabharwal, P., Zhang, M., Meyers, C. L. F., & Sockanathan, S. (2013) · Science · doi:10.1126/science.1231921 · Cited by 118 · cited 1×
“GDPD5 also has important functions in regulating neuron differentiation through glycosylphosphatidylinositolanchor cleavage of reversion-inducing cysteine-rich protein with kazal motifs (RECK) (166), which, further downstream, leads to inactivation of the Notch signaling pathway.”
Background
Cited by
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Lipid composition of the cancer cell membrane
Szlasa, W., Zendran, I., Zalesińska, A., Tarek, M., & Kulbacka, J. (2020) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-020-09846-4 · Cited by 435
Phosphatidylserine synthesis controls oncogenic B cell receptor signaling in B cell lymphoma
Omi, J., Kato, T., Yoshihama, Y., Sawada, K., Kono, N., & Aoki, J. (2024) · Journal of Cell Biology · doi:10.1083/jcb.202212074 · Cited by 18
“Cancer cells also employ sophisticated changes in phospholipid metabolism to achieve efficient survival and expansion (Cheng et al., 2016).”
Metadata
- Authors
- Cheng, M., Bhujwalla, Z. M., & Glunde, K.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2016-12-27
- Volume
- 6
- Pages
- 266-266
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2567989936
- Cited by
- 223
- References
- 3
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Phospholipid Metabolism in Cancer. https://app.cochat.ai/papers/10.3389/fonc.2016.00266
- The paper
- Cheng, M., Bhujwalla, Z. M., & Glunde, K. (2016). Targeting Phospholipid Metabolism in Cancer. Frontiers in Oncology. https://doi.org/10.3389/fonc.2016.00266
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.